- Home
- EDSA vs LPCN Comparison
EDSA vs LPCN Comparison
Compare EDSA & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- LPCN
- Stock Information
- Founded
- EDSA 2015
- LPCN 1997
- Country
- EDSA Canada
- LPCN United States
- Employees
- EDSA N/A
- LPCN N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- LPCN Health Care
- Exchange
- EDSA Nasdaq
- LPCN Nasdaq
- Market Cap
- EDSA 15.9M
- LPCN 16.1M
- IPO Year
- EDSA N/A
- LPCN N/A
- Fundamental
- Price
- EDSA $2.11
- LPCN $2.95
- Analyst Decision
- EDSA Strong Buy
- LPCN Strong Buy
- Analyst Count
- EDSA 2
- LPCN 2
- Target Price
- EDSA $13.00
- LPCN $9.00
- AVG Volume (30 Days)
- EDSA 38.0K
- LPCN 36.3K
- Earning Date
- EDSA 08-08-2025
- LPCN 08-05-2025
- Dividend Yield
- EDSA N/A
- LPCN N/A
- EPS Growth
- EDSA N/A
- LPCN N/A
- EPS
- EDSA N/A
- LPCN N/A
- Revenue
- EDSA N/A
- LPCN $4,208,119.00
- Revenue This Year
- EDSA N/A
- LPCN N/A
- Revenue Next Year
- EDSA N/A
- LPCN N/A
- P/E Ratio
- EDSA N/A
- LPCN N/A
- Revenue Growth
- EDSA N/A
- LPCN N/A
- 52 Week Low
- EDSA $1.55
- LPCN $2.68
- 52 Week High
- EDSA $5.18
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- EDSA 42.63
- LPCN 37.54
- Support Level
- EDSA $2.02
- LPCN $2.92
- Resistance Level
- EDSA $2.35
- LPCN $3.25
- Average True Range (ATR)
- EDSA 0.14
- LPCN 0.19
- MACD
- EDSA -0.03
- LPCN -0.04
- Stochastic Oscillator
- EDSA 18.00
- LPCN 4.41
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.